Adil Duru
Director of Business Development Glycostem
Adil joined Glycostem in 2020 as Senior Research Manager and led the development of novel engineered NK cell platforms and clinical research as team lead, as well as contributed to multiple projects such as mechanism of action and combination therapies. Since October 2023, Adil serves as the Director of Business Development at Glycostem.
Previously, Adil performed his PhD and post-doctoral studies at Karolinska Institute, Sweden, on MHC-class-I restricted-peptide based immunomodulation of T cells and NK cells, and on developing novel genetic modification strategies for NK cells, respectively. From 2015 until 2020, Adil worked as an Assistant Professor/PI at the Nova Southeastern University (NSU) Cell Therapy Institute, FL, USA, focussed his research on investigating NK cell interactions with tumors and developing innovative novel NCR-, TCR- and CAR-based genetically modified NK cell immunotherapies. Furthermore, Adil established and directed the Cell Therapy Core Facility at NSU, for the design, development and pre-clinical evaluation of novel cell therapy products. Additionally, Adil is a co-founder and shareholder of Vycellix Inc. and has 20+ peer reviewed publications as well as multiple patent applications.
Seminars
- Demonstrating safety and feasibility of umbilical cord blood–derived CD34 NK cell therapy with no dose-limiting toxicities or GVHD
- Showcasing in vivo persistence, activation, and cytotoxicity confirming biological activity in AML patients
- Highlighting preliminary clinical responses with blast reduction and MRD clearance supporting next-phase development
Advancing NK-based therapies from preclinical proof-of-concept to meaningful clinical outcomes depends on identifying the right patients and monitoring their responses effectively. Predictive biomarkers, translational analytics, and innovative assay platforms are critical to reduce trial risk, guide dosing, and validate therapeutic mechanisms. This workshop explores state-of-the-art strategies to integrate biomarker discovery and translational science into NK therapy development to de-risk programs and speed regulatory and clinical milestones.
Join this workshop to:
- Understand emerging biomarkers for patient selection, persistence, and therapeutic response in autoimmunity and oncology
- Explore cutting-edge analytical tools, single-cell sequencing, spatial transcriptomics, and functional NK assays to uncover actionable insights
- Review case-based examples of how translational strategies can refine trial design, optimize dosing, and improve go/no-go decisions
